Head-to-head · free

Merck vs NanoViricides, Inc.

MRK vs NNVC — return on capital, cash generation, margins and balance sheet side by side.

MRK

2 / 2

measures where MRK leads

NNVC

0 / 2

measures where NNVC leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureMRK · FY2025NNVC · FY2026
Revenue$65.0B—
Net income$18.3B(8.2M)
Revenue growth (yearly, multi-year)7.5%—
Free cash flow$12.4B(7.8M)
Free cash flow margin19.0%—
Net cash / (debt)——
ROIC19.0%—
Return on equity36.9%—
Gross margin74.8%—
Operating margin34.0%—
Net debt / EBITDA1.29x—

Figures are as reported by each company; latest fiscal year shown.

Where Merck's cash went (FY2025)

Capital spending
$4.1B
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full MRK profile →

Where NanoViricides, Inc.'s cash went (FY2026)

Capital spending
$84317
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full NNVC profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons